Hennion & Walsh Asset Management, Inc. Crispr Therapeutics Ag Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.1 Billion
- Q4 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 44,305 shares of CRSP stock, worth $1.92 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
44,305
Previous 40,568
9.21%
Holding current value
$1.92 Million
Previous $1.91 Million
8.55%
% of portfolio
0.08%
Previous 0.09%
Shares
7 transactions
Others Institutions Holding CRSP
# of Institutions
491Shares Held
59.8MCall Options Held
1.1MPut Options Held
1.72M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$389 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA7.93MShares$343 Million0.07% of portfolio
-
State Street Corp Boston, MA2.99MShares$130 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$120 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$119 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.38B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....